BioCardia Reports Q3 2026 Net Loss of $1.8 Million
BioCardia reported a Q3 2026 net loss of $1.8M, up from $1.5M a year earlier. Cash reserves were $2.2M, with $1.7M used in operations. The company made progress on CardiAMP, Helix, and Heart3D programs, with key regulatory milestones expected in 2027.
How this was made

The 30-second read
Why it matters
The disclosed loss and cash burn highlight financing needs, but progress on regulatory submissions may offer a catalyst later in 2027.
Market read
Micro‑cap earnings with a modest loss; likely limited immediate market movement but important for investors tracking biotech cash‑flow risk.
What to watch
Potential cash infusion from partnership with CART‑Tech or future grant funding could mitigate liquidity concerns.
Background
BioCardia is a clinical‑stage biotech developing cardiac therapies. The Q3 filing provides the latest financial snapshot and updates on its CardiAMP, Helix, and Heart3D programs.
Ticker impact
BioCardia disclosed Q3 2026 net loss of $1.8M and cash position, the first public filing of these results.
likely downward pressure as investors price the widening loss and limited liquidity.
Micro‑cap earnings with a net loss and minimal cash typically trigger sell‑offs.
Market effects
Limited impact on the broader biotech sector; results reflect early‑stage development risk.
Primarily relevant to US small‑cap investors; no broader regional effect.
Minimal global relevance.
Counterpoint
If the upcoming regulatory submissions succeed, the short‑term loss may be outweighed by long‑term upside.
Key entities
- companyBioCardia, Inc.
Clinical‑stage biotech reporting Q3 2026 results.
- partnerCART‑Tech
Collaborator on the Heart3D platform.

